Security key
690469101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 36,211,271
- Total 13F value
- $47,075,130
- Share change
- +264,419
- Put/Call ratio
- 44%
- SEC-reported price per share
- $1.30
- Number of holders
- 80
- Value change
- +$6,613,712
- Number of buys
- 41
- Number of sells
- 36
- Shares outstanding
- 186,597,793
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
80
Top holders
10
OVID full security history
Ownership snapshot
Full 13F holder table
Ovid Therapeutics Inc. SEC filings
Ovid Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of OVID - Ovid Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Madison Avenue Partners, LP
Disclosed value leader
TAKEDA PHARMACEUTICAL CO LTD
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
Lead comparable stake: 4%
13D/G row: Madison Avenue Partners, LP
Showing 1-6 of 15 holder rows.
Quick read
Madison Avenue Partners, LP leads the comparable SEC ownership view at 4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Madison Avenue Partners, LP's linked filing trail.
Comparable ownership
Top 5
Madison Avenue Partners, LP
4%
Rubric Capital Management LP
0.67%
TAKEDA PHARMACEUTICAL CO LTD
4%
BVF INC/IL
2.1%
VANGUARD GROUP INC
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP |
13D/G
13F
Company
|
4%
|
$969,800
2,852,352 shares
|
$0 | 31 Dec 2024 |
| Rubric Capital Management LP |
13F
13D/G
Company
|
0.67%
from 13D/G
|
$157,868
478,533 shares
|
— | 30 Jun 2025 |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
Company
|
4%
|
$2,485,380
7,531,996 shares
|
— | 30 Jun 2025 |
| BVF INC/IL |
13F
Company
|
2.1%
|
$1,271,375
3,853,818 shares
|
— | 30 Jun 2025 |
| VANGUARD GROUP INC |
13F
Company
|
1.4%
|
$869,918
2,636,115 shares
|
— | 30 Jun 2025 |
| Sio Capital Management, LLC |
13F
Company
|
1.2%
|
$736,337
2,232,000 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
80
Shares
36,211,271
Rows available
80
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
69
Q3 2025 holders
80
Holder diff
11
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|